<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5632011</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx162.141</article-id><article-id pub-id-type="publisher-id">ofx162.141</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Oral Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Immunogenicity of Inactivated Varicella Zoster Vaccine (ZV<sub>IN</sub>) in Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Recipients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Boeckh</surname><given-names>Michael</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Arvin</surname><given-names>Ann</given-names></name><degrees>MD, FIDSA, FPIDS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Mullane</surname><given-names>Kathleen</given-names></name><degrees>DO, FIDSA</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Winston</surname><given-names>Drew J</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0004">4</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Janice (Wes)</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="AF0005">5</xref></contrib><contrib contrib-type="author"><name><surname>Pergam</surname><given-names>Steven</given-names></name><degrees>MD, MPH, FIDSA</degrees><xref ref-type="aff" rid="AF0006">6</xref></contrib><contrib contrib-type="author"><name><surname>Hurtado</surname><given-names>Kimberly</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Pang</surname><given-names>Lei</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ingi</given-names></name><degrees>MD, MSCE</degrees><xref ref-type="aff" rid="AF0008">8</xref></contrib><contrib contrib-type="author"><name><surname>Popmihajlov</surname><given-names>Zoran</given-names></name><degrees>MD, MS</degrees><xref ref-type="aff" rid="AF0007">7</xref></contrib><contrib contrib-type="author"><collab>on behalf of the V212 Protocol 001 Study Team</collab><xref ref-type="aff" rid="AF0001">1</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Fred Hutchinson Cancer Research Center</institution>, <addr-line>Seattle, Washington</addr-line>;</aff><aff id="AF0002">
<label>2</label>
<institution>Division of ID/Department of Ped, Stanford University School of Medicine</institution>, <addr-line>Stanford, California</addr-line>;</aff><aff id="AF0003">
<label>3</label>
<institution>Medicine, University of Chicago Medicine</institution>, <addr-line>Chicago, Illinois</addr-line>;</aff><aff id="AF0004">
<label>4</label>
<institution>University of California at Los Angeles Medical Center</institution>, <addr-line>Los Angeles, California</addr-line>;</aff><aff id="AF0005">
<label>5</label>
<institution>Division of Blood and Marrow Transplant and Division of Infectious Diseases, Department of Medicine, Stanford University School of Medicine</institution>, <addr-line>Stanford, California</addr-line>;</aff><aff id="AF0006">
<label>6</label>
<institution>Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center</institution>, <addr-line>Seattle, Washington</addr-line>;</aff><aff id="AF0007">
<label>7</label>
<institution>Merck &#x00026; Co., Inc.</institution>, <addr-line>Kenilworth, New Jersey</addr-line>;</aff><aff id="AF0008">
<label>8</label>
<institution>Merck &#x00026; Co., Inc.</institution>, <addr-line>North Wales</addr-line>, <country>Pennsylvania</country></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 229. Miscellaneous Advances in Vaccinology</p><p>
<italic>Saturday, October 7, 2017: 10:30 AM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S60</fpage><lpage>S60</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx162.141.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Recipients of auto-HSCT have an increased risk of herpes zoster (HZ) infection; however, live attenuated varicella-zoster virus (VZV) vaccine is contraindicated in these patients. In this pivotal Phase III study (V212-001; NCT01229267) inactivated VZV vaccine (ZV<sub>IN</sub>) reduced the rate of HZ infection compared with placebo (estimated vaccine efficacy, 63.8%) and was well tolerated. Immunogenicity of ZV<sub>IN</sub>in recipients of auto-HSCT was assessed in the Phase III study as an exploratory objective.</p></sec><sec id="s2"><title>Methods</title><p>Adults undergoing auto-HSCT were randomized to receive either ZV<sub>IN</sub>(<italic>n</italic>&#x000a0;=&#x000a0;560) or placebo (<italic>n</italic>&#x000a0;=&#x000a0;564), administered in a 4-dose regimen. Doses 1 through 4 were administered ~30&#x000a0;days before and ~30, ~60, and ~90&#x000a0;days following auto-HSCT. VZV-specific immune responses were measured at Day 1, ~28&#x000a0;days post-vaccinations 3 and 4, and annually until the end of the study. VZV-specific antibody responses were measured by glycoprotein enzyme-linked immunosorbent assay (gpELISA) in all patients; cell-mediated immune responses were measured by VZV interferon-gamma enzyme-linked immunospot (IFN-&#x003b3; ELISPOT) assay in a randomized subset of patients (<italic>n</italic>&#x000a0;=&#x000a0;403).</p></sec><sec id="s3"><title>Results</title><p>Geometric mean titers (GMT) were significantly higher and the ratios of the gpELISA and IFN-&#x003b3; ELISPOT were significantly greater in the ZV<sub>IN</sub>group compared with the placebo group (Tables 1 and&#x000a0;2).</p><table-wrap id="T1" orientation="portrait" position="float"><caption><p>Table&#x000a0;1. GMT 28&#x000a0;days post-dose 4 (PD4)</p></caption><table frame="box" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Vaccine</bold>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>Placebo</bold>
</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">
<bold>gpELISA</bold>
</td><td align="left" valign="bottom" rowspan="1" colspan="1">
<bold><italic>n</italic>&#x000a0;=&#x000a0;102</bold>
</td><td align="left" valign="bottom" rowspan="1" colspan="1">
<bold><italic>n</italic>&#x000a0;=&#x000a0;108</bold>
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">241.8 (95% CI: 186.2, 313.9)</td><td align="left" valign="bottom" rowspan="1" colspan="1">105.8 (95% CI: 84.6, 132.3)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">
<bold>IFN-&#x003b3; ELISPOT</bold>
</td><td align="left" valign="bottom" rowspan="1" colspan="1">
<bold><italic>n</italic>&#x000a0;=&#x000a0;102</bold>
</td><td align="left" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic>
<bold>= 116</bold>
</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1"/><td align="left" valign="bottom" rowspan="1" colspan="1">62.8 (95% CI: 45.8, 86.2)</td><td align="left" valign="bottom" rowspan="1" colspan="1">10.4 (95% CI: 7.9, 13.7)</td></tr></tbody></table></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><caption><p>Table&#x000a0;2. Ratios of geometric mean fold rise between the vaccine and placebo groups (ZV<sub>IN</sub>/placebo)</p></caption><table frame="box" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>gpELISA</bold>
<bold>(<italic>n</italic>&#x000a0;=&#x000a0;764)</bold>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<bold>IFN-&#x003b3; ELISPOT</bold>
<bold>(<italic>n</italic>&#x000a0;=&#x000a0;339)</bold>
</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Pre-vaccination and 28&#x000a0;days &#x02028;PD4</bold>
</td><td align="left" valign="bottom" rowspan="1" colspan="1">1.79 (95% CI: 1.39, 2.32)</td><td align="left" valign="bottom" rowspan="1" colspan="1">5.41 (95% CI: 3.60, 8.12)</td></tr><tr><td align="left" valign="bottom" rowspan="1" colspan="1">
<bold>Pre-vaccination and 1&#x000a0;year &#x02028;PD4</bold>
</td><td align="left" valign="bottom" rowspan="1" colspan="1">1.30 (95% CI: 0.99, 1.71)</td><td align="left" valign="bottom" rowspan="1" colspan="1">4.12 (95% CI: 2.62, 6.47)</td></tr></tbody></table></table-wrap></sec><sec id="s4"><title>Conclusion</title><p>ZV<sub>IN</sub> elicited higher VZV-specific humoral and cell-mediated responses in adult auto-HSCT recipients when compared with placebo ~28&#x000a0;days and ~1&#x000a0;year post-dose 4.&#x000a0;These results indicate that ZV<sub>IN</sub> is immunogenic in these patients who are ineligible for live attenuated HZ vaccine, which is consistent with previously observed clinical efficacy.</p></sec><sec id="s5"><title>Disclosures</title><p>
<bold>M. Boeckh</bold>, Merck: Investigator, Research Contractor and Scientific Advisor, Consulting fee and Research support; GlaxoSmithKline: Research Contractor, Research support; <bold>A. Arvin</bold>, Merck: Scientific Advisor, Consulting fee; <bold>K. Mullane</bold>, Merck: Scientific Advisor, Grant recipient; <bold>D. J.&#x000a0;Winston</bold>, Merck: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient; <bold>J. Brown</bold>, Merck: Clinical adjudication and site investigator and Investigator, Consulting fee; Cellerant Therapeutics: Consultant, Cellerant developing and executing clinical trials of myeloid progenitor cells in neutropenia for which I&#x000a0;hold the patent; <bold>S. Pergam</bold>, Merck: Consultant and Investigator, Consulting fee; <bold>K. Hurtado</bold>, Merck: Employee and Shareholder, Salary; <bold>L. Pang</bold>, Merck: Employee and Shareholder, Salary; <bold>I. Lee</bold>, Merck: Employee, Salary; <bold>Z. Popmihajlov</bold>, Merck &#x00026; Co., Inc.: Employee and Shareholder, Salary</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>